Compounds for treating cancer

1. A compound having the following formula or a pharmaceutically acceptable salt thereof:

wherein:

R independently represent a hydrogen atom, a halogen atom, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 4 )alkoxy group, a phenoxy group, or a (C 1 -C 3 )alkyl group optionally mono-substituted by a hydroxyl group,

R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group,

n is 1, 2, or 3,

n′ is 1 or 2,

R′ is a hydrogen atom, a halogen atom, a (C 1 -C 3 )alkyl group, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a morpholinyl group, a morpholino group, a N-methylpiperazinyl group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 4 )alkoxy group, or a —CN group, and

R″ is a hydrogen atom or a (C 1 -C 4 )alkyl group, with the proviso that:

R′ and R are not simultaneously a hydrogen atom,

when R′ is a hydrogen atom, R is not a —NO 2 group or a —NH 2 group, and

when n is 2 and R′ is a hydrogen atom, R is not a COOC 2 H 5 group or a chlorine atom.

2. The compound of claim 1 , wherein R is a (C 1 -C 3 )fluoroalkoxy group.

3. The compound of claim 1 , wherein R′ is a —NR 1 R 2 group.

4. The compound of claim 1 , wherein R′ is a morpholinyl, a morpholino group, or a N-methylpiperazinyl group.

5. A compound selected from the group consisting of:

(143) 4-N,4-N-dimethyl-7-N[4-(trifluoromethoxy)phenyl]quinoline-4,7-diamine;

(144) 4-(morpholin-4-yl)-N-[4-(trifluoromethoxy)phenyl]quinolin-7-amine;

(166) N-(4-methoxyphenyl)-4-(4-methylpiperazin-1-yl)quinolin-7-amine;

(167) 4-methoxy-N[4-(trifluoromethoxy)phenyl]quinolin-7-amine; or

their pharmaceutically acceptable salts.

6. The compound of claim 5 , wherein the pharmaceutically acceptable salts are selected from hydrobromide, citrate, trifluoroacetate, ascorbate, hydrochloride, tartrate, triflate, maleate, mesylate, formate, acetate or fumarate.

7. A pharmaceutical composition comprising at least one compound as defined in claim 1 .

8. A pharmaceutical composition comprising at least one compound as defined in claim 2 .

9. A pharmaceutical composition comprising at least one compound as defined in claim 3 .

10. A pharmaceutical composition comprising at least one compound as defined in claim 4 .

11. A pharmaceutical composition comprising at least one compound as defined in claim 5 .

12. A pharmaceutical composition comprising at least one compound as defined in claim 6 .

13. The pharmaceutical composition according to claim 7 , further comprising a pharmaceutically acceptable support.

14. The pharmaceutical composition according to claim 8 , further comprising a pharmaceutically acceptable support.

15. The pharmaceutical composition according to claim 9 , further comprising a pharmaceutically acceptable support.

16. The pharmaceutical composition according to claim 10 , further comprising a pharmaceutically acceptable support.

17. The pharmaceutical composition according to claim 11 , further comprising a pharmaceutically acceptable support.

18. The pharmaceutical composition according to claim 12 , further comprising a pharmaceutically acceptable support.

19. A method of treating cancer selected from the group consisting of breast cancer, pancreatic cancer, prostate cancer, lung cancer, non-small cell lung cancer, thyroid cancer, liver cancer, and kidney cancer, comprising:

contacting a cell with at least one compound of formula (Iq) or a pharmaceutically acceptable salt thereof:

wherein:

R independently represent a hydrogen atom, a halogen atom, a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO 2 group, a —NR 1 R 2 group, a (C 1 -C 4 )alkoxy group, a phenoxy group, or a (C 1 -C 3 )alkyl group optionally mono-substituted by a hydroxyl group,

R 1 and R 2 are independently a hydrogen atom or a (C 1 -C 3 )alkyl group,

n is 1, 2, or 3,

n′ is 1 or 2,

R′ is a hydrogen atom, a halogen atom, a (C 1 -C 3 )alkyl group, a hydroxyl group, a —COOR 1 group, a —NO 2 group, a —NR 1 R 2 group, a morpholinyl group, a morpholino group, a N-methylpiperazinyl group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 4 )alkoxy group, or a —CN group, and

R″ is a hydrogen atom or a (C 1 -C 4 )alkyl group.

20. The method of claim 19 , wherein:

R independently represent a hydrogen atom, a (C 1 -C 3 )alkoxy group, or a (C 1 -C 3 )fluoroalkoxy group, and

R′ is a hydrogen atom, a —NR 1 R 2 group, a N-methylpiperazinyl group, a (C 1 -C 3 )alkoxy group, or a morpholino group.

21. The method of claim 19 , wherein R is a (C 1 -C 3 )fluoroalkoxy group.

22. A method of treating cancer selected from the group consisting of breast cancer, pancreatic cancer, prostate cancer, lung cancer, non-small cell lung cancer, thyroid cancer, liver cancer, and kidney cancer comprising contacting a cell with at least one compound selected from the group consisting of:

(143) 4-N,4-N-dimethyl-7-N[4-(trifluoromethoxy)phenyl]quinoline-4,7-diamine;

(144) 4-(morpholin-4-yl)-N-[4-(trifluoromethoxy)phenyl]quinolin-7-amine;

(166) N-(4-methoxyphenyl)-4-(4-methylpiperazin-1-yl)quinolin-7-amine;

(167) 4-methoxy-N[4-(trifluoromethoxy)phenyl]quinolin-7-amine; or

pharmaceutically acceptable salts thereof.

23. The method of claim 22 , wherein the pharmaceutically acceptable salts are selected from hydrobromide, citrate, trifluoroacetate, ascorbate, hydrochloride, tartrate, triflate, maleate, mesylate, formate, acetate, or fumarate.

24. The method of claim 19 , further comprising a step of administering the compound to a patient in need of cancer treatment.

25. The method of claim 24 , wherein the compound is administered to the patient orally.

26. The method of claim 22 , further comprising a step of administering the compound to a patient in need of cancer treatment.

27. The method of claim 26 , wherein the compound is administered to the patient orally.